BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
322.90
-8.50 (-2.56%)
At close: Dec 5, 2025, 4:00 PM EST
322.40
-0.50 (-0.15%)
After-hours: Dec 5, 2025, 7:07 PM EST
BeOne Medicines AG Revenue
BeOne Medicines AG had revenue of $1.41B in the quarter ending September 30, 2025, with 41.00% growth. This brings the company's revenue in the last twelve months to $4.97B, up 50.43% year-over-year. In the year 2024, BeOne Medicines AG had annual revenue of $3.81B with 54.96% growth.
Revenue (ttm)
$4.97B
Revenue Growth
+50.43%
P/S Ratio
7.02
Revenue / Employee
$452,062
Employees
11,000
Market Cap
35.73B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ONC News
- 1 day ago - BeOne Medicines Continues To Execute In Q3 - Seeking Alpha
- 9 days ago - Artisan International Small-Mid Fund Q3 2025 Performance Review - Seeking Alpha
- 9 days ago - U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma - Business Wire
- 15 days ago - BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025 - Business Wire
- 18 days ago - BeOne Medicines AG (ONC) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 18 days ago - Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma - Business Wire
- 25 days ago - BeOne Medicines AG (ONC) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript - Seeking Alpha
- 4 weeks ago - BeOne Medicines AG (ONC) Q3 2025 Earnings Call Transcript - Seeking Alpha